What is Drugs Made In America Acquisition II Equity-to-Asset?
Drugs Made In America Acquisition IIDMII 15 Equity-to-Asset is 0.96 as of Mar. 2026, which is 1500% above its 10-year median of 0.06. GuruFocus rates DMII with a GF Scoreâ„¢ of 15/100. The stock has 1 warning sign investors should review. Among 565 Diversified Financial Services companies, Drugs Made In America Acquisition II ranks better than 80% on this metric.
DMII'
s Equity-to-Asset Range Over the Past 10 Years
Min: -1.89 Med: 0.06 Max: 0.97
Current: 0.96
During the past 2 years, the highest Equity to Asset Ratio of Drugs Made In America Acquisition II was 0.97. The lowest was -1.89. And the median was 0.06.
DMII's Equity-to-Asset is ranked better than 80% of 565
companies
in the Diversified Financial Services industry
Industry Median: 0.9
vs DMII: 0.96
Drugs Made In America Acquisition II (NAS:DMII) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Drugs Made In America Acquisition II Equity-to-Asset Related Terms
Drugs Made In America Acquisition II Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Drugs Made In America Acquisition II Equity-to-Asset Chart
Drugs Made In America Acquisition II Annual Data
Trend
Dec24
Dec25
Equity-to-Asset
-0.85
0.97
Drugs Made In America Acquisition II Quarterly Data
DMII vs BCSS, EVAC, CEPF: Equity-to-Asset Comparison
For the Shell Companies subindustry, Drugs Made In America Acquisition II's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Drugs Made In America Acquisition II Equity-to-Asset vs Diversified Financial Services Industry
For the Diversified Financial Services industry and Financial Services sector, Drugs Made In America Acquisition II's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Drugs Made In America Acquisition II's Equity-to-Asset falls into.
Drugs Made In America Acquisition II Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Drugs Made In America Acquisition II (DMII) has a Equity-to-Asset of 0.96 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Drugs Made In America Acquisition II and its competitors. This is 1500% above median its historical median of 0.06. According to the industry distribution chart, Drugs Made In America Acquisition II ranks #113 out of 565 companies in the Diversified Financial Services industry, placing it in the top 20%.
Is Drugs Made In America Acquisition II's Equity-to-Asset too high?
Drugs Made In America Acquisition II's current Equity-to-Asset of 0.96 is 1500% above median its 10-year median of 0.06. The Diversified Financial Services industry median Equity-to-Asset is 0.90. Drugs Made In America Acquisition II's value of 0.96 is 6.7% above this industry median. Based on the distribution chart, Drugs Made In America Acquisition II ranks #113 out of 565 companies in the Diversified Financial Services industry, which is in the top quartile — a strong position relative to peers. Overall, Drugs Made In America Acquisition II has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Drugs Made In America Acquisition II's Equity-to-Asset compare to BCSS and EVAC?
According to the Diversified Financial Services industry distribution chart, Drugs Made In America Acquisition II ranks #113 out of 565 companies for Equity-to-Asset. This places Drugs Made In America Acquisition II in the top 20% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.90. Drugs Made In America Acquisition II's value of 0.96 is 6.7% above this benchmark. While the company's 10-year median is 0.06 vs. the industry median of 0.90, Drugs Made In America Acquisition II has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Diversified Financial Services company?
The median Equity-to-Asset among Diversified Financial Services companies is 0.90, based on 565 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Drugs Made In America Acquisition II's current Equity-to-Asset of 0.96 is 6.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Drugs Made In America Acquisition II and its competitors. For the Diversified Financial Services industry, the median Equity-to-Asset is 0.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Drugs Made In America Acquisition II's current Equity-to-Asset is 0.96, which is 1500% above median its own 10-year median of 0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Drugs Made In America Acquisition II stock overvalued right now?
Drugs Made In America Acquisition II (DMII) has a current Equity-to-Asset of 0.96. The current Equity-to-Asset is 0.96, which is 1500% above median its 10-year median of 0.06 and 6.7% above the Diversified Financial Services industry median of 0.90. Drugs Made In America Acquisition II's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Drugs Made In America Acquisition II (DMII), the current Equity-to-Asset is 0.96 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Drugs Made In America Acquisition II Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DMII has been successfully added to your 